病毒阴性炎症性心肌病的免疫抑制治疗:TIMIC试验20年随访
TIMIC随机双盲安慰剂对照试验纳入85例活检证实的病毒阴性慢性炎症性心肌病患者,泼尼松联合硫唑嘌呤治疗6个月使88%患者心功能改善。长期随访(最长20年)显示,与倾向评分匹配的未治疗对照相比,免疫抑制治疗组心血管死亡和心脏移植风险显著更低,左心室射血分数持续改善。
要点
- 病毒阴性炎症性心肌病患者接受6个月免疫抑制治疗可改善心功能。
- 长期随访中免疫抑制治疗与较低的心血管死亡和心脏移植风险相关。
- 复发性心肌炎对再次应用TIMIC方案有应答。
核心结论
- 病毒阴性炎症性心肌病可从免疫抑制治疗中获益,且长期随访仍显示获益。
- 疾病复发似乎对再次应用TIMIC方案有应答。
研究设计与样本
- 随机、双盲、安慰剂对照TIMIC试验纳入85例心内膜心肌活检证实的病毒阴性慢性炎症性心肌病患者。
- 患者接受泼尼松联合硫唑嘌呤(n=43)或安慰剂(n=42)治疗6个月。
- 长期随访比较全部85例原试验患者(A组)与1:2倾向评分匹配的未接受TIMIC方案治疗的对照队列(B组)。
主要发现
- 免疫抑制治疗使88%的患者心功能改善,而安慰剂组无患者改善。
- 长期随访中,B组心血管死亡风险显著高于A组(HR 6.77;95%CI 2.36-19.45)。
- B组心脏移植风险显著高于A组(HR 7.92;95%CI 1.80-34.88)。
- A组左心室射血分数较B组持续改善(HR 7.24;95%CI 3.05-17.18)。
- B组更多患者接受了植入式心律转复除颤器植入,两组复发性心肌炎发生率相似。
临床怎么用
- 对活检证实的病毒阴性慢性炎症性心肌病患者,可考虑泼尼松联合硫唑嘌呤治疗6个月。
- 长期随访中应关注心功能变化及复发,复发时可再次应用TIMIC方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Long-term results of the Tailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy (TIMIC) trial protocol have been evaluated. METHODS AND RESULTS: Eighty-five patients with endomyocardial biopsy-proven virus-negative chronic inflammatory cardiomyopathy were enrolled in the randomized, double-blind, placebo-controlled TIMIC trial and received prednisone and azathioprine (n = 43) vs. placebo (n = 42) for 6 months. Immunosuppressive treatment promoted an improvement in cardiac function in 88% of the cases compared with none of the patients in the placebo group, which were switched to a 6-month immunosuppressive therapy at the end of the 6-month study period. Long-term (up to 20 years) clinical outcomes of the whole cohort of 85 patients originally enrolled in the TIMIC trial (Group A) were compared with those of a 1:2 propensity score-matched control cohort of patients untreated with the TIMIC protocol (Group B) and followed for a comparable period of time. The primary outcome was a composite of cardiovascular death and heart transplantation. At long-term follow-up, the risk of cardiovascular death [hazard ratio (HR) 6.77; 95% confidence interval (CI) 2.36-19.45] and heart transplantation (HR 7.92; 95% CI 1.80-34.88) was significantly higher in Group B patients. Group A showed a persistent improvement in the left ventricular ejection fraction compared with Group B (HR 7.24; 95% CI 3.05-17.18). A higher number of Group B patients underwent implantable cardioverter defibrillator implantation. The incidence of recurrent myocarditis was similar between groups, and patients with evidence of a recurrent cardiac inflammatory process promptly responded to a TIMIC protocol application. CONCLUSION: Virus-negative inflammatory cardiomyopathy benefits from immunosuppressive therapy even after long-term follow-up. Recurrence appears to respond to a new TIMIC protocol application.
引用
- Chimenti C, Russo MA, Frustaci A, et al. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur Heart J. 2022. PMID: 35831932. doi:10.1093/eurheartj/ehac348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。